Reducing primary care antibiotic use 'not enough' to counter antimicrobial resistance

Drug resistant E. coli infections were not halted by reduction, according to new report

Read on PharmaTimes

Positive Phase III results for Valneva’s chikungunya vaccine

Neutralising antibody titers were observed in 98.5% of subjects

Read on PharmaTimes

NICE pens two-year collaboration with the Academic Health Science Network

Agreement will support use of the 'best evidence-based healthcare' in the NHS

Read on PharmaTimes

16- and 17-year-olds should receive first COVID-19 vaccine, advises JCVI

Vaccine side effects rare and outweighed by the benefits

Read on PharmaTimes

BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma

Phase III trials did not demonstrate sufficient clinical benefit.

Read on PharmaTimes

1 2 3

Top of page

Industry News

Drug resistant E.coli infections were not halted by reduction, according to new report.
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us